

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions, and listings, of claims in this application.

Listing of Claims

1. (Currently amended) A composition comprising a protein in crystalline form wherein the protein consists of SEQ ID NO:3, and wherein the protein crystal has a crystal lattice in a P₃2₁ space group and unit cell dimensions, +/- 5%, of a = 72.12Å, b = 72.12Å and c = 241.62Å.
2. (Previously presented) A composition according to claim 1 wherein the protein is present in the protein crystal as a dimer.
3. (Cancelled)
4. (Currently amended) A composition according to claim 1 wherein the ~~protein~~ crystal diffracts X-rays for a determination of structure coordinates to a resolution ~~having a value less~~ higher than 3.0 Angstroms.
- 5-8. (Cancelled)
9. (Currently amended) A method comprising:
forming a crystallization volume comprising a precipitant solution and a protein that consists of SEQ ID NO:3, wherein the protein crystal has a crystal lattice in a P₃2₁ space group and unit cell dimensions, +/- 5%, of a = 72.12Å, b = 72.12 Å and c = 241.62 Å; and
forming a crystalline form of the protein in the crystallization volume.
10. (Previously presented) A method according to claim 9 wherein the protein is present in the protein crystal as a dimer.
11. (Cancelled)
12. (Currently amended) A method according to claim 9 wherein the ~~protein~~ crystal diffracts X-rays for a determination of structure coordinates to a resolution ~~having a value less~~ higher than 3.0 Angstroms.
- 13-14. (Cancelled)

15. (Previously presented) A method according to claim 9, the method further comprising:
 diffracting the protein crystal to produce a diffraction pattern; and
 solving the structure of the protein from the diffraction pattern.
16. (Cancelled)
17. (Currently amended) A ~~composition comprising a~~ soluble protein consisting of SEQ ID NO:3.
- 18-25 (Cancelled)
26. (Previously presented) A method according to claim 15, the method further comprising:
 performing rational drug design using the solved structure; and
 identifying an entity that associates with the protein.
27. (Previously presented) A method according to claim 26 wherein the protein is present in the protein crystal as a dimer.
- 28-29. (Cancelled).
30. (Previously presented) A method according to claim 26, the method further comprising:
 selecting one or more entities based on the rational drug design; and
 contacting the selected entities with the protein.
31. (Previously presented) A method according to claim 26, the method further comprising measuring an activity of the protein when contacted with the one or more entities.
32. (Previously presented) method according to claim 26, the method further comprising:
 comparing activity of the protein in a presence of and in the absence of the one or more entities;
and
 selecting entities where activity of the protein changes depending whether a particular entity is present.
33. (Previously presented) A method according to claim 26, the method further comprising:

Serial No.: 10/601,324
Filing Date: June 20, 2003

contacting cells expressing the protein with the one or more entities; and
detecting a change in a phenotype of the cells when a particular entity is present.

34. (New) An isolated soluble protein consisting of residues 596-900 of SEQ ID NO:1.

35. (New) A composition comprising a protein in crystalline form wherein the protein consists of 596-900 of SEQ ID NO:1, and wherein the protein crystal has a crystal lattice in a $P3_221$ space group and unit cell dimensions, $\pm 5\%$, of $a = 72.12\text{\AA}$, $b = 72.12\text{\AA}$ and $c = 241.62\text{\AA}$.

36. (New) A method comprising:
forming a crystallization volume comprising a precipitant solution and a protein that consists of 596-900 of SEQ ID NO:1, wherein the protein crystal has a crystal lattice in a $P3_221$ space group and unit cell dimensions, $\pm 5\%$, of $a = 72.12\text{\AA}$, $b = 72.12\text{\AA}$ and $c = 241.62\text{\AA}$; and
forming a crystalline form of the protein in the crystallization volume.

37. (New) An isolated non-crystalline protein consisting of residues 596-900 of SEQ ID NO:1.

38. (New) A non-crystalline protein consists of SEQ ID NO:3.